about
Current Landscape of Antiviral Drug DiscoveryHepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genesHepatitis B: future curative strategiesIntrahepatic Transcriptional Signature Associated with Response to Interferon-α Treatment in the Woodchuck Model of Chronic Hepatitis BFuture Therapy for Hepatitis B Virus: Role of ImmunomodulatorsPrevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challengesGenome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and KoreanThe hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymesAssociation of preexisting drug-resistance mutations and treatment failure in hepatitis B patientsHepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agentsSustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis BAntiviral natural products and herbal medicines.Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activityInterferons: Success in anti-viral immunotherapy.Precore mutation of hepatitis B virus may contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis.Hepatitis B virus management to prevent reactivation after chemotherapy: a review.Natural Killer Cells in Viral Hepatitis.Reversible bilateral ototoxicity in a patient with chronic hepatitis B during peginterferon alpha-2a treatment.Short-term spontaneous fluctuations of HBV DNA levels in a Senegalese population with chronic hepatitis B.The hepatitis B virus ribonuclease H as a drug targetHow further suppression of virus replication could improve current HBV treatment.The chimpanzee model for hepatitis B virus infection.Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cellsAIC649 Induces a Bi-Phasic Treatment Response in the Woodchuck Model of Chronic Hepatitis B.Duck Hepatitis B Virus cccDNA Amplification Efficiency in Natural Infection Is Regulated by Virus Secretion Efficiency.Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy.Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections.Transcriptomic analysis of the woodchuck model of chronic hepatitis BAntiviral Efficacy and Host Innate Immunity Associated with SB 9200 Treatment in the Woodchuck Model of Chronic Hepatitis BTranscriptome Analysis and Comparison of Marmota monax and Marmota himalayana.Antiviral Efficacy and Host Immune Response Induction during Sequential Treatment with SB 9200 Followed by Entecavir in Woodchucks.The Smc5/6 Complex Restricts HBV when Localized to ND10 without Inducing an Innate Immune Response and Is Counteracted by the HBV X Protein Shortly after InfectionHepatitis B virus efficiently infects non-adherent hepatoma cells via human sodium taurocholate cotransporting polypeptideGenetic variation in the vitamin D pathway CYP2R1 gene predicts sustained HBeAg seroconversion in chronic hepatitis B patients treated with pegylated interferon: A multicenter studyClinical correlation between HBV infection and concomitant bacterial infections.Molecular dissection of HBV evasion from restriction factor tetherin: A new perspective for antiviral cell therapyGetting to grips with hepatitis.Identification of an intrahepatic transcriptional signature associated with self-limiting infection in the woodchuck model of hepatitis B.GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees.
P2860
Q26766639-3F45EA70-65D1-4C48-968C-B51D1D00D420Q26772317-FF014DD8-C5FF-4A49-BFB4-2092DC68BC40Q27011623-8EA20A31-064F-4F59-859B-A1B5987575AAQ27318089-6948F4F5-CD32-4BB4-9D2B-398525D64722Q28078148-8CFCDF82-E1D4-4C46-99B0-DD57972B0562Q28272678-A9214411-C9DC-4EE9-8CCB-77AAEE914DD8Q28480585-DDD772D8-D462-42E6-BB4A-6F6CF1C03EDAQ28485228-2DBF574F-A87A-4758-AA05-2CB63C2CDE39Q28535003-EB708B4E-9C06-47CE-ABDE-D6948DDA71C5Q28538891-C6D9C23E-1DEB-445B-BEE2-0084C3CC1056Q33419607-63001382-8502-4631-8CF9-91C4D215DF3BQ33657624-0B552EBB-E27B-4DB0-ABDD-D86E464C444AQ33911464-79E9D748-3933-4AF8-822F-1D717FA18B97Q34276038-92F12648-3BDC-4040-9D27-57FD39E2EE74Q34295883-85E5D70E-6A2B-4F50-B1E4-891022E4B340Q34397738-FBF29402-91BD-4C00-AD8A-E5EF3F1FA9C1Q34505690-99E3B1CD-1D0F-4C1D-91D1-307A6373428FQ35222364-DF475EF9-0DED-4353-A87E-375E7A5C1DF9Q35224148-C7F6939A-5BED-4513-BD06-75276C92E73DQ35582561-D043A24F-2015-4CA6-A5D8-A95409AF002FQ35622347-3BF13FB5-BFF6-4E94-98A8-4DD09114C8B4Q35664171-AA858287-5949-4631-BD0C-8C8CEEEFCCBCQ35746110-A050DC03-2A7A-4955-9FAC-9409423E0AF0Q35786326-29768BB9-9962-4838-AB66-902691240E4CQ35866293-1111E9DB-38FB-4977-B330-AD35A84013FDQ35880401-E9A235D4-B6CD-46DF-A258-3822D406826FQ35992400-0AC8B7E4-F48B-4FA7-8963-E2A0A04BF9A6Q36073739-96A00AFE-5315-4C0A-87B4-20762CFA1A30Q36106479-209396EE-29A2-4FC9-8A7B-F79CB4967FAEQ36110296-6F3A4744-6222-43FC-861B-A00F2DCBC24AQ36180507-BAF6D78F-9632-4FC8-87FE-F33CBE9D6DEEQ36240367-6360A945-1BA1-4150-B88F-B000DB08C05DQ36251481-BFD1308E-25D4-4FD8-9520-70D31C148420Q36305699-545B71ED-61A1-442F-93DB-66B2B31D8884Q36309024-5B1976F4-0759-4610-956B-151D22C3002DQ36346211-62584847-12DE-4532-B33E-131B9A788AC7Q36355811-522E5EB0-E7EE-47B5-9014-D91D1B24B357Q36361478-E1AD5F7C-45BF-431F-ACE8-39DBC77E3C6DQ36476515-B6CDF9C1-D1F7-483B-AF42-4A93473B94EBQ36950984-BF9E4BC2-05E1-4A38-A285-6817DD5B6CA5
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hepatitis B therapy.
@en
Hepatitis B therapy.
@nl
type
label
Hepatitis B therapy.
@en
Hepatitis B therapy.
@nl
prefLabel
Hepatitis B therapy.
@en
Hepatitis B therapy.
@nl
P2860
P356
P1476
Hepatitis B therapy.
@en
P2093
Anna S Lok
Hellan Kwon
P2860
P2888
P304
P356
10.1038/NRGASTRO.2011.33
P407
P577
2011-03-22T00:00:00Z